Catalyst Pharmaceuticals, Inc. Board of Directors

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Mr. Richard John Daly M.B.A.

Mr. Richard John Daly M.B.A.

President, CEO & Director

Dr. Steven R. Miller Ph.D.

Dr. Steven R. Miller Ph.D.

Executive VP, COO & Chief Scientific Officer

Mr. Pete Curry Sr.

Mr. Pete Curry Sr.

Vice President of Sales

Ms. Mary Coleman

Ms. Mary Coleman

VP & Head of Investor Relations

Dr. Stanley Iyadurai M.D., Ph.D.

Dr. Stanley Iyadurai M.D., Ph.D.

Senior Vice President of Medical Affairs & Drug Discovery

Mr. Michael W. Kalb CPA

Mr. Michael W. Kalb CPA

Executive VP, Treasurer & CFO

Dr. Gary Ingenito M.D., Ph.D.

Dr. Gary Ingenito M.D., Ph.D.

Chief Medical & Regulatory Officer

Mr. Jeffrey Del Carmen

Mr. Jeffrey Del Carmen

Executive VP & Chief Commercial Officer

Mr. Brian Elsbernd J.D.

Mr. Brian Elsbernd J.D.

Chief Compliance Officer & Chief Legal Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.